With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 5, 2017. This JAMA Onc article reports FOLFOXIRI-bevacizumab converts 40% of patients with unresectable metastatic colon cancer to resectable with 25% getting an R0 resection. So you heard it here first, FOLFOXIRIB. And did someone say SBRT?